Filing Flows › TG Therapeutics (TGTX) › Q4 2025
TG Therapeutics (TGTX) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 27, 2026
TG Therapeutics (TGTX) reported revenue of $193M for the fourth quarter 2025 (Q4 2025), +78% from a year earlier and +19% from the quarter before. Operating margin was 26.2%, net earnings $23.0M (12.0% of revenue).
TG Therapeutics, Q4 2025: revenue $193M (+78% year over year), operating margin 26.2%, net earnings $23.0M, operating cash flow $19.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $193M | +19% | +78% |
| Operating profit | $50.5M | +72% | +69% |
| Net earnings | $23.0M | -94% | -1% |
| Operating cash flow | $19.7M | — | — |
| Free cash flow | $19.6M | — | — |
What changed
Revenue was $192.6M in Q4 2025, up 78% year over year and up 19% from the previous quarter. Product was the largest line at 98% of revenue.
Operating profit was $50.5M, a 26.2% margin (down 1.5 points year over year). Of the extra revenue versus Q4 2024, 24% reached operating profit, below the 28% margin then. Total costs grew 82% against revenue growth of 78%. The fastest-growing cost line was Cost of revenue (+148%). Net earnings were $23.0M, down 1% year over year. The effective tax rate was 48.9%.
Operating cash flow was $19.7M, 85% of net earnings. Non-cash charges added back $21K of depreciation and amortization and $15.7M of share-based compensation. Working capital and other items used $19.0M. Capital expenditures of $67K left free cash flow of $19.6M.
Questions
What was TG Therapeutics' revenue in the fourth quarter 2025?
TG Therapeutics (TGTX) reported revenue of $193M for the fourth quarter 2025 (Q4 2025), +78% from a year earlier and +19% from the quarter before.
Was TG Therapeutics profitable in the fourth quarter 2025?
Operating profit was $50.5M (26.2% of revenue) and net earnings $23.0M.
Source: TG Therapeutics 10-K on SEC EDGAR.